In high-risk outpatients with COVID-19, neither colchicine nor aspirin reduced disease progression or death at 45 d.

Authors
Category Primary study
JournalAnnals of internal medicine
Year 2023
Eikelboom JW, Jolly SS, Belley-Cote EP, et al. Colchicine and aspirin in community patients with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial. Lancet Respir Med. 2022;10:1160-8. 36228639.
Epistemonikos ID: ca137f15a75a8850e41ea830694877b151d31f64
First added on: Feb 07, 2023